BMO Capital Markets reissued their outperform rating on shares of Mallinckrodt PLC (NYSE:MNK) in a report issued on Tuesday.

A number of other equities analysts have also commented on the company. Zacks Investment Research lowered Mallinckrodt PLC from a hold rating to a sell rating in a research note on Tuesday, October 4th. Morgan Stanley restated a buy rating and set a $82.00 price objective on shares of Mallinckrodt PLC in a research note on Wednesday, September 21st. Piper Jaffray Cos. raised their price objective on Mallinckrodt PLC from $103.00 to $112.00 and gave the stock an overweight rating in a research note on Wednesday, August 24th. Mizuho lowered their price objective on Mallinckrodt PLC from $91.00 to $89.00 and set a buy rating on the stock in a research note on Thursday, September 29th. Finally, Leerink Swann restated an outperform rating and set a $92.00 price objective on shares of Mallinckrodt PLC in a research note on Saturday, November 19th. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Mallinckrodt PLC has an average rating of Buy and an average price target of $89.44.

Analyst Recommendations for Mallinckrodt PLC (NYSE:MNK)

Mallinckrodt PLC (NYSE:MNK) opened at 52.42 on Tuesday. The firm has a market cap of $5.65 billion, a price-to-earnings ratio of 9.88 and a beta of 1.62. The stock’s 50 day moving average price is $61.54 and its 200 day moving average price is $66.60. Mallinckrodt PLC has a 52 week low of $50.90 and a 52 week high of $85.83.

Mallinckrodt PLC (NYSE:MNK) last posted its quarterly earnings data on Tuesday, November 29th. The company reported $2.04 EPS for the quarter, topping the Zacks’ consensus estimate of $2.01 by $0.03. Mallinckrodt PLC had a return on equity of 17.78% and a net margin of 16.39%. The firm had revenue of $887.20 million for the quarter, compared to analyst estimates of $880.10 million. During the same quarter last year, the company earned $1.84 EPS. The company’s revenue was up 13.9% on a year-over-year basis. On average, equities research analysts predict that Mallinckrodt PLC will post $7.66 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2016/11/30/mallinckrodt-plc-mnk-given-outperform-rating-at-bmo-capital-markets.html.

Several institutional investors have recently added to or reduced their stakes in the stock. Emerald Acquisition Ltd. acquired a new position in Mallinckrodt PLC during the second quarter valued at about $35,680,000. Dimensional Fund Advisors LP raised its position in Mallinckrodt PLC by 93.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,187,203 shares of the company’s stock valued at $72,152,000 after buying an additional 573,682 shares in the last quarter. Chartwell Investment Partners LLC acquired a new position in Mallinckrodt PLC during the third quarter valued at about $31,922,000. FMR LLC raised its position in Mallinckrodt PLC by 142.8% in the second quarter. FMR LLC now owns 712,469 shares of the company’s stock valued at $43,304,000 after buying an additional 419,057 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in Mallinckrodt PLC by 36.5% in the second quarter. Acadian Asset Management LLC now owns 1,299,378 shares of the company’s stock valued at $78,975,000 after buying an additional 347,188 shares in the last quarter. 86.51% of the stock is owned by institutional investors.

About Mallinckrodt PLC

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.

5 Day Chart for NYSE:MNK

Receive News & Stock Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related stocks with our FREE daily email newsletter.